Prostate-specific membrane antigen expression predicts recurrence of papillary thyroid carcinoma after total thyroidectomy

Abstract

Background Prostate-specific membrane antigen (PSMA) overexpression has been observed in the endothelial neovasculature of several solid malignancies. This study aimed to identify PSMA expression in the primary tumor of classical papillary thyroid carcinoma (PTC) and assess the correlation between the degree of PSMA expression and recurrence. Methods We reviewed the electronic medical records of patients who underwent total thyroidectomy and central neck dissection, with or without lateral neck dissection, for classical PTC between 2009 and 2014 at our institution. Recurrence was defined as a structural disease based on histological confirmation on follow-up. Fifty-one patients with the recurrent structural disease were matched, using a propensity score matching method, to patients with no disease evidence during follow-up. Clinicopathological and follow-up data were collected for 102 patients. The monoclonal mouse anti-human PSMA/FOLH1/NAALADase I antibody was used for staining the primary tumor. The score of PSMA expression was classified as negative (< 5% positivity), weak (5–10 % positivity), moderate (11–49% positivity), and strong (more than 50% positivity). Clinicopathological factors were compared between patients with low and high PSMA expression. Moreover, whether the degree of PSMA expression and clinicopathological factors could predict recurrence was investigated. Cox proportional hazard regression models were used to evaluate the risk of recurrence. Results There was no significant difference in clinicopathological factors between low (negative or weak) and high (moderate or strong) PSMA expression. Gross extrathyroidal extension (ETE), absence of chronic lymphocytic thyroiditis, and high PSMA expression were all associated with lower recurrence-free survival (RFS) rate in a univariate analysis. In multivariate analysis, gross ETE (hazard ratio [HR], 2.279; 95% confidence interval [CI], 1.257−4.132; p = 0.007) and high PSMA expression (HR, 1.895; 95% CI, 1.073−3.348; p = 0.028) were associated with poor RFS. Conclusions High PSMA expression in the primary tumor was a significant factor in predicting recurrence in classic PTC. PSMA could be a potential biomarker for personalized management for PTC.

Follow-up after radioiodine remnant ablation in differentiated thyroid cancer: the view of nuclear medicine physician

“…В течение последних 2 лет в зарубежной литературе опубликован ряд работ, в которых представлены возможности проведения пептидно-рецепторной радионуклидной терапии с использованием радиоактивно меченных аналогов соматостатина ( 177 Lu-DOTA-TATE), продемонстрирована перспективность в лечении радиойодрефрактерного ДРЩЖ с объективной частотой ответа в виде уменьшения опухоли на 20-60 % по критериям Response evaluation criteria in solid tumours 1.1 (RECIST 1.1) [68][69][70]. В то же время некоторые пилотные исследования показали повышенную экспрессию PSMA-рецепторов у больных радиойодрефрактерным ДРЩЖ при выполнении ПЭТ-КТ c 18 F-PSMA и 68 Ga-PSMA, что с учетом тераностического принципа делает возможным применение в будущем радиолигандной терапии 177 Lu-DOTA-PSMA-617 у данной категории пациентов [71,72].…”